Boehringer Ingelheim
Big PharmaBoehringer Ingelheim is a major pharmaceutical company focused on Respiratory, Metabolic, Oncology. Key products include PRAXBIND.
FDA Novel Drug Designations
(2022-2025)See 3 novel approvals →
Boehringer Ingelheim at a Glance
- Strong track record with 83% execution quality across 1171 trials
- Leading 14 drug targets across portfolio
Boehringer Ingelheim's Key Drugs
Boehringer Ingelheim's core commercial portfolio centers on JARDIANCE, STRIVERDI RESPIMAT, STIOLTO RESPIMAT, spanning Respiratory and Metabolic — its most strategically important drugs approved in the last 15 years.
Type 2 Diabetes
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Type 2 Diabetes
Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim's Recent FDA Approvals
Boehringer Ingelheim secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Boehringer Ingelheim's Therapeutic Areas
Boehringer Ingelheim's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Metabolic, across 2 biologic and 21 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Boehringer Ingelheim's Top Competitors
Boehringer Ingelheim's closest competitors by therapeutic-area and drug-target overlap include Novartis, AstraZeneca, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Boehringer Ingelheim Pipeline Snapshot
Boehringer Ingelheim has 496 active clinical programs from ClinicalTrials.gov — 176 Phase 3, 120 Phase 2 and 200 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 195/231 completed
- • Speed: 12 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (18)
Discontinued (1)
Company Info
- First Approval
- 1961-12-06
- Latest
- 2026-08-14
- Applications
- 58
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges